** Shares of Divi's Laboratories DIVI.NS settle down 2.6%
6,096.20 rupees, their worst day since mid-August
** DIVI second-biggest pct loser among pharma stocks
.NIPHARM which is up 0.2%
** Novartis NOVN.S failed to persuade U.S. court on
Wednesday to halt generic version of its blockbuster heart drug
Entresto
** Divi's Labs supplies active pharmaceutical ingredients
for Entresto
** Stock had dropped 4% in mid-August when Novartis lost
initial bid to block generic version of Entresto
** DIVI among 11 stocks on 20-member pharma index rated
"hold", rest rated "buy" or higher - LSEG data
** Stock up ~56% YTD vs pharma index's 34% gain
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))